Signatory Authority Decisional Memorandum to the File

First Page		Document Content
Chemistry Organofluorides Medullary thyroid cancer Angiogenesis inhibitors Vandetanib Response Evaluation Criteria in Solid Tumors End point of clinical trials Thyroid neoplasm Multiple endocrine neoplasia Medicine Oncology Thyroid cancer		Signatory Authority Decisional Memorandum to the File Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 277,79 KB Share Document on Facebook

	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6 DocID: 1gamh - View Document
	PDF Document DocID: 1aW8t - View Document
	Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G DocID: 1axH7 - View Document
	New target: FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute New target : FGFR, c-MET DocID: 19uI3 - View Document
	PUBLIC SUMMARY DOCUMENT Product: Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application DocID: 197HX - View Document